.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Teva
Baxter
Accenture
Argus Health
Dow
Queensland Health
Chinese Patent Office
Healthtrust

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,726,918

« Back to Dashboard

Which drugs does patent 6,726,918 protect, and when does it expire?


Patent 6,726,918 protects OZURDEX and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 6,726,918

Title: Methods for treating inflammation-mediated conditions of the eye
Abstract:Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee: Oculex Pharmaceuticals, Inc. (Sunnyvale, CA)
Application Number:09/693,008
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AllerganOZURDEXdexamethasoneIMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF UVEITIS
AllerganOZURDEXdexamethasoneIMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF MACULAR EDEMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,726,918

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,063,031Implants and methods for treating inflammation-mediated conditions of the eye► Subscribe
9,012,437Implants and methods for treating inflammation-mediated conditions of the eye► Subscribe
8,242,099Implants and methods for treating inflammation-mediated conditions of the eye► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,726,918

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina029567► Subscribe
Austria339185► Subscribe
Australia2001273166► Subscribe
Australia2005246995► Subscribe
Australia7316601► Subscribe
Brazil0112361► Subscribe
Canada2414680► Subscribe
Germany60123055► Subscribe
Denmark1296645► Subscribe
European Patent Office1296645► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Deloitte
AstraZeneca
Dow
Covington
Citi
Express Scripts
Johnson and Johnson
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot